These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 22438913)

  • 1. Heterodimerization of glycosylated insulin-like growth factor-1 receptors and insulin receptors in cancer cells sensitive to anti-IGF1R antibody.
    Kim JG; Kang MJ; Yoon YK; Kim HP; Park J; Song SH; Han SW; Park JW; Kang GH; Kang KW; Oh DY; Im SA; Bang YJ; Yi EC; Kim TY
    PLoS One; 2012; 7(3):e33322. PubMed ID: 22438913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting non-small cell lung cancer cells by dual inhibition of the insulin receptor and the insulin-like growth factor-1 receptor.
    Vincent EE; Elder DJ; Curwen J; Kilgour E; Hers I; Tavaré JM
    PLoS One; 2013; 8(6):e66963. PubMed ID: 23826179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular predictors of sensitivity to the insulin-like growth factor 1 receptor inhibitor Figitumumab (CP-751,871).
    Pavlicek A; Lira ME; Lee NV; Ching KA; Ye J; Cao J; Garza SJ; Hook KE; Ozeck M; Shi ST; Yuan J; Zheng X; Rejto PA; Kan JL; Christensen JG
    Mol Cancer Ther; 2013 Dec; 12(12):2929-39. PubMed ID: 24107449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ropivacaine suppresses tumor biological characteristics of human hepatocellular carcinoma via inhibiting IGF-1R/PI3K/AKT/mTOR signaling axis.
    Zhang R; Lian Y; Xie K; Cai Y; Pan Y; Zhu Y
    Bioengineered; 2021 Dec; 12(2):9162-9173. PubMed ID: 34696683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of IGF-I receptor monoclonal antibody against human gastrointestinal carcinomas is independent of k-ras mutation status.
    Ii M; Li H; Adachi Y; Yamamoto H; Ohashi H; Taniguchi H; Arimura Y; Carbone DP; Imai K; Shinomura Y
    Clin Cancer Res; 2011 Aug; 17(15):5048-59. PubMed ID: 21642381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of anti-insulin-like growth factor I receptor monoclonal antibody cixutumumab in mesothelioma is highly correlated with insulin growth factor-I receptor sites/cell.
    Kalra N; Zhang J; Yu Y; Ho M; Merino M; Cao L; Hassan R
    Int J Cancer; 2012 Nov; 131(9):2143-52. PubMed ID: 22323052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epithelial-mesenchymal transition predicts sensitivity to the dual IGF-1R/IR inhibitor OSI-906 in hepatocellular carcinoma cell lines.
    Zhao H; Desai V; Wang J; Epstein DM; Miglarese M; Buck E
    Mol Cancer Ther; 2012 Feb; 11(2):503-13. PubMed ID: 22161861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.
    Tovar V; Alsinet C; Villanueva A; Hoshida Y; Chiang DY; Solé M; Thung S; Moyano S; Toffanin S; Mínguez B; Cabellos L; Peix J; Schwartz M; Mazzaferro V; Bruix J; Llovet JM
    J Hepatol; 2010 Apr; 52(4):550-9. PubMed ID: 20206398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Abnormal expression of insulin-like growth factor-I receptor and inhibitory effect of its transcription intervention on nude mice xenograft tumor].
    Yao M; Yan XD; Cai Y; Gu JJ; Yang XL; Pan LH; Wang L; Yao DF
    Zhonghua Gan Zang Bing Za Zhi; 2016 Nov; 24(11):846-851. PubMed ID: 27978931
    [No Abstract]   [Full Text] [Related]  

  • 10. IGF-I receptor as an emerging potential molecular-targeted for hepatocellular carcinoma in vitro and in vivo.
    Yao M; Wang L; Yang J; Yan X; Cai Y; Yao D
    Tumour Biol; 2016 Nov; 37(11):14677-14686. PubMed ID: 27623941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake.
    Shang Y; Mao Y; Batson J; Scales SJ; Phillips G; Lackner MR; Totpal K; Williams S; Yang J; Tang Z; Modrusan Z; Tan C; Liang WC; Tsai SP; Vanderbilt A; Kozuka K; Hoeflich K; Tien J; Ross S; Li C; Lee SH; Song A; Wu Y; Stephan JP; Ashkenazi A; Zha J
    Mol Cancer Ther; 2008 Sep; 7(9):2599-608. PubMed ID: 18790743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of two insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumor response.
    Dong J; Demarest SJ; Sereno A; Tamraz S; Langley E; Doern A; Snipas T; Perron K; Joseph I; Glaser SM; Ho SN; Reff ME; Hariharan K
    Mol Cancer Ther; 2010 Sep; 9(9):2593-604. PubMed ID: 20716637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IGF1R Derived PI3K/AKT Signaling Maintains Growth in a Subset of Human T-Cell Acute Lymphoblastic Leukemias.
    Gusscott S; Jenkins CE; Lam SH; Giambra V; Pollak M; Weng AP
    PLoS One; 2016; 11(8):e0161158. PubMed ID: 27532210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
    Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
    Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma.
    Pivonello C; Negri M; De Martino MC; Napolitano M; de Angelis C; Provvisiero DP; Cuomo G; Auriemma RS; Simeoli C; Izzo F; Colao A; Hofland LJ; Pivonello R
    Oncotarget; 2016 Mar; 7(9):9718-31. PubMed ID: 26756219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
    Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
    Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer.
    Sachdev D; Singh R; Fujita-Yamaguchi Y; Yee D
    Cancer Res; 2006 Feb; 66(4):2391-402. PubMed ID: 16489046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of hepatocellular carcinoma cell growth by an anti-insulin-like growth factor-I receptor monoclonal antibody.
    Yue L; Wang Y; Wang H; Gao H; Liang J; Sui A; Xiang J; Zhou F; Xu C; Zhao W; Liang W; Yao R
    Oncol Rep; 2012 Oct; 28(4):1453-60. PubMed ID: 22895605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
    Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
    Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
    Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.